Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - monobasic potassium phosphate, quantity: 136.1 mg/ml - injection, concentrated - excipient ingredients: water for injections - treatment of severe hypophosphataemia (serum levels less than 0.3 mmol/l) and other degrees of hypophosphataemia when oral therapy is not possible. the cause of hypophosphataemia should be identified and treated.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - minoxidil, quantity: 10 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; maize starch; colloidal anhydrous silica - indications as at 1 january 1991 : indicated as adjunctive therapy in adults with severe refractory hypertension which has failed to respond to extensive multiple therapy. when used in combination with an accompanying diuretic and beta-blocker, minoxidil (loniten) has been shown to reverse encephalopathy and retinopathy in severe hypertensives.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - magnesium sulfate heptahydrate, quantity: 493 mg/ml - injection, concentrated - excipient ingredients: water for injections - indication as at 8 january 2004: parenteral administration of magnesium is indicated in the treatment of acute hypomagnesaemia. magnesium salts are also indicated to prevent hypomagnesaemia in patients receiving total parenteral nutrition. magnesium sulfate is also indicated in the prevention and treatment of life threatening seizures in the treatment of toxemias of pregnancy (pre-eclampsia and eclampsia).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - papaverine hydrochloride, quantity: 12 mg/ml - injection, solution - excipient ingredients: water for injections - papaverine hydrochloride injection is indicated for the treatment of erectile dysfunction.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - promethazine hydrochloride, quantity: 25 mg/ml - injection, solution - excipient ingredients: disodium edetate; sodium metabisulfite; glacial acetic acid; sodium acetate; water for injections - indication as 8 january 2004: promethazine hydrochloride injection bp is indicated for the following conditions: treatment of allergic reactions such as: uncomplicated allergic conditions of the immediate type, e.g. pruritus, urticaria and angioedema, when oral therapy is impossible or contraindicated. treatment and prevention of vomiting including: motion sickness; drug induced nausea; prevention and control of nausea and vomiting associated with certain types of anaesthesia and surgery, such as procedures with a high incidence of post-operative vomiting (e.g. gynaecological surgery, strabismus or middle ear surgery, and electroconvulsive therapy); in patients with a past history of motion sickness or post-operative vomiting; and in patients in whom avoidance of vomiting is crucial (e.g. neurosurgery and eye surgery). promethazine has sedative effects and it is also used in: pre-operative, post-operative and obstetric (during labour) sedation.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - noradrenaline (norepinephrine) acid tartrate monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - noradrenaline (norepinephrine) acid tartrate monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - morphine tartrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - morphine tartrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - alprostadil -